New cancer drug enters first human trials for multiple advanced cancers

NCT ID NCT06545331

Recruiting now Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called XB010 for advanced solid tumors that have stopped responding to other treatments. Researchers aim to find a safe and tolerable dose of XB010, both alone and combined with another cancer drug (pembrolizumab). The study will also look for early signs that the drug can shrink tumors in patients with cancers like lung, breast, head and neck, and esophageal cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Exelixis Clinical Site #1
RECRUITING

Austin, Texas, 78758, United States
Exelixis Clinical Site #10
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Exelixis Clinical Site #11
RECRUITING

Fairfax, Virginia, 22031, United States
Exelixis Clinical Site #12
RECRUITING

Atlanta, Georgia, 30322, United States
Exelixis Clinical Site #13
RECRUITING

London, England, W1G 6AD, United Kingdom
Exelixis Clinical Site #14
RECRUITING

Manchester, England, M20 4BX, United Kingdom
Exelixis Clinical Site #15
RECRUITING

Chicago, Illinois, 60637, United States
Exelixis Clinical Site #16
RECRUITING

London, England, W1T 7HA, United Kingdom
Exelixis Clinical Site #17
RECRUITING

Leicester, England, LE1 5WW, United Kingdom
Exelixis Clinical Site #18
RECRUITING

Orlando, Florida, 32827, United States
Exelixis Clinical Site #19
RECRUITING

Los Angeles, California, 90095, United States
Exelixis Clinical Site #2
RECRUITING

Fairfax, Virginia, 22031, United States
Exelixis Clinical Site #3
RECRUITING

Huntersville, North Carolina, 28078, United States
Exelixis Clinical Site #4
RECRUITING

Irvine, California, 92618, United States
Exelixis Clinical Site #5
RECRUITING

St Louis, Missouri, 63110, United States
Exelixis Clinical Site #6
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
Exelixis Clinical Site #7
RECRUITING

Dallas, Texas, 74246, United States
Exelixis Clinical Site #8
RECRUITING

Houston, Texas, 77030, United States
Exelixis Clinical Site #9
RECRUITING

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

ESOPHAGEAL SQUAMOUS CELL CANCER HEAD AND NECK SQUAMOUS CELL CANCER HORMONE-RECEPTOR-POSITIVE BREAST CANCER LOCALLY ADVANCED OR METASTATIC SOLID TUMORS NSCLC (NON-SMALL CELL LUNG CANCER) TRIPLE NEGATIVE BREAST CANCER (TNBC)